Eli Lilly and Company LLY
today announced data from a Phase III trial comparing the effects of FORTEO^®
(teriparatide [rDNA origin] injection) and risedronate on back pain in
postmenopausal women with osteoporotic vertebral fractures. The study showed
no difference between FORTEO and risedronate on the primary endpoint of at
least a 30 percent reduction in worst back pain from baseline to six months of
therapy, as assessed by a numeric rating scale in each treatment group.[1]
However, there were statistically significant differences in favor of FORTEO
in some exploratory measures, including greater increases in bone mineral
density (BMD) and fewer patients with new vertebral fractures. The results of
the study are published in the August issue of Osteoporosis International.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in